Glipten Adverse Reactions



Ajanta Pharma Phil


Ajanta Pharma Phil
Full Prescribing Info
Adverse Reactions
Hypoglycemia: In clinical trials using Teneligliptin as monotherapy, the incidence of hypoglycemia was 1.1%. The incidence of hypoglycemia when Teneligliptin was used in combination with metformin, pioglitazone, and α-glucosidase inhibitors was 1.1%, 1.5%, and 1.3%, respectively, and not significantly different from incidence rates in placebo treated subjects. Hypoglycemic episodes were of mild intensity, not dose related, and did not cause any subjects to discontinue treatment. The incidence of hypoglycemia is increased when Teneligliptin is added to treatment with a glinide (3.8%) and a sulfonylurea (8.9%). Serious hypoglycemic symptoms with or without loss of consciousness have been reported when DPP-4 inhibitors are combined with sulfonylureas. Therefore, when Teneligliptin is used in combination with sulfonylurea, the dose of the sulfonylurea should be reduced. (See Table 7.)

Click on icon to see table/diagram/image
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in